{"disease":{"id":"non-alcoholic-steatohepatitis-nash","name":"non alcoholic steatohepatitis nash"},"drugs":{"marketed":[{"drug_id":"resmetirom","indication_name":"Noncirrhotic Nonalcoholic Steatohepatitis (NASH)","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"RESMETIROM","company_name":"","drug_phase":"marketed","molecular_target":"","drug_class":"Thyroid Hormone Receptor beta Agonist [EPC]","quality_score":30,"revenue":null,"mechanism":null}],"pipeline":[{"drug_id":"pf-05221304","indication_name":"Nonalcoholic steatohepatitis (NASH)","indication_type":"pipeline","phase":"Phase 2","line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"PF-05221304","generic_name":"pf-05221304","company_name":"Pfizer Inc.","drug_phase":"discontinued","molecular_target":"Acetyl-CoA carboxylase (ACC1 and ACC2)","drug_class":"Acetyl-CoA carboxylase inhibitor","quality_score":27,"revenue":null,"mechanism":"Selective inhibitor of acetyl-CoA carboxylase (ACC1/ACC2) that reduces hepatic lipogenesis and promotes fatty acid oxidation."}],"offLabel":[],"totalMarketed":1,"totalPipeline":1},"trials":{"data":[{"nct_id":"NCT03151473","title":"Longitudinal Observational Study Of Chinese With NAFLD/NASH","phase":"","overall_status":"RECRUITING","enrollment_count":20000,"lead_sponsor_name":"Humanity and Health Research Centre","has_results":false},{"nct_id":"NCT07336563","title":"ENDOCARE-SCREEN: Metabolic Liver Dysfunction Screening Study","phase":"","overall_status":"NOT_YET_RECRUITING","enrollment_count":10000,"lead_sponsor_name":"Jarosław Drobnik","has_results":false},{"nct_id":"NCT05423327","title":"Genetic Data Collection in Adult Participants to Identify Genetic Variants of Known Importance in Non-alcoholic Steatohepatitis (NASH)","phase":"NA","overall_status":"TERMINATED","enrollment_count":5311,"lead_sponsor_name":"Regeneron Pharmaceuticals","has_results":false},{"nct_id":"NCT02548351","title":"Randomized Global Phase 3 Study to Evaluate the Impact on NASH With Fibrosis of Obeticholic Acid Treatment","phase":"PHASE3","overall_status":"TERMINATED","enrollment_count":2477,"lead_sponsor_name":"Intercept Pharmaceuticals","has_results":true},{"nct_id":"NCT07180745","title":"Empagliflozin Versus Statins in Non-Alcoholic Fatty Liver Disease","phase":"PHASE4","overall_status":"NOT_YET_RECRUITING","enrollment_count":400,"lead_sponsor_name":"Badr University","has_results":false},{"nct_id":"NCT02855164","title":"Study of Safety and Efficacy of Tropifexor (LJN452) in Patients With Non-alcoholic Steatohepatitis (NASH)","phase":"PHASE2","overall_status":"TERMINATED","enrollment_count":350,"lead_sponsor_name":"Novartis Pharmaceuticals","has_results":true},{"nct_id":"NCT04255069","title":"A Study to Evaluate the Efficacy and Safety of JKB-122 in Patients With NASH and Fibrosis","phase":"PHASE2","overall_status":"UNKNOWN","enrollment_count":300,"lead_sponsor_name":"TaiwanJ Pharmaceuticals Co., Ltd","has_results":false},{"nct_id":"NCT04771273","title":"A Study to Test Safety and Efficacy of Survodutide (BI456906) in Adults With Non-alcoholic Steatohepatitis (NASH) and Fibrosis (F1-F3)","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":295,"lead_sponsor_name":"Boehringer Ingelheim","has_results":true},{"nct_id":"NCT04052516","title":"A Phase 2b Study of Icosabutate in Fatty Liver Disease","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":280,"lead_sponsor_name":"NorthSea Therapeutics B.V.","has_results":true},{"nct_id":"NCT02443116","title":"Study of NGM282 in Patients With Nonalcoholic Steatohepatitis (NASH)","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":254,"lead_sponsor_name":"NGM Biopharmaceuticals, Inc","has_results":true},{"nct_id":"NCT03008070","title":"Phase 2b Study in NASH to Assess IVA337","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":247,"lead_sponsor_name":"Inventiva Pharma","has_results":true},{"nct_id":"NCT04065841","title":"Efficacy, Safety and Tolerability of the Combination of Tropifexor & Licogliflozin and Each Monotherapy, Compared With Placebo in Adult Patients With NASH and Liver Fibrosis.","phase":"PHASE2","overall_status":"TERMINATED","enrollment_count":234,"lead_sponsor_name":"Novartis Pharmaceuticals","has_results":true},{"nct_id":"NCT04880031","title":"A Study of BOS-580 in Obese Subjects at Risk for, or With Biopsy-confirmed, Nonalcoholic Steatohepatitis (NASH) With an Extension","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":231,"lead_sponsor_name":"Boston Pharmaceuticals","has_results":false},{"nct_id":"NCT02781584","title":"Safety, Tolerability, and Efficacy of Selonsertib, Firsocostat, and Cilofexor in Adults With Nonalcoholic Steatohepatitis (NASH)","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":220,"lead_sponsor_name":"Gilead Sciences","has_results":true},{"nct_id":"NCT06309992","title":"A Study to Test Whether Survodutide Helps People Living With Obesity or Overweight and With a Confirmed or Presumed Liver Disease Called Non-alcoholic Steatohepatitis (NASH) to Reduce Liver Fat and to Lose Weight (SYNCHRONIZE-MASLD)","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":218,"lead_sponsor_name":"Boehringer Ingelheim","has_results":false},{"nct_id":"NCT05623189","title":"HTD1801 in Adults With Nonalcoholic Steatohepatitis and Liver Fibrosis Who Have Type 2 Diabetes or Pre-Diabetes","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":218,"lead_sponsor_name":"HighTide Biopharma Pty Ltd","has_results":false},{"nct_id":"NCT05989711","title":"IMPACT TRIAL: Efficacy and Safety of Pemvidutide in Subjects With Nonalcoholic Steatohepatitis (NASH)","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":212,"lead_sponsor_name":"Altimmune, Inc.","has_results":false},{"nct_id":"NCT03517540","title":"Study of Safety, Tolerability, and Efficacy of a Combination Treatment of LJN452 and CVC in Adult Patients With NASH and Liver Fibrosis","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":193,"lead_sponsor_name":"Novartis Pharmaceuticals","has_results":true},{"nct_id":"NCT06168383","title":"To Evaluate the Efficacy and Safety of HSK31679 in Chinese Patients With Non-Alcoholic Steatohepatitis (NASH) .","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":186,"lead_sponsor_name":"Haisco Pharmaceutical Group Co., Ltd.","has_results":false},{"nct_id":"NCT05692492","title":"A Randomized, Double-blind, Placebo-controlled Study of ZSP1601 in Adult Subjects With Nonalcoholic Steatohepatitis (NASH)","phase":"PHASE2","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":180,"lead_sponsor_name":"Guangdong Raynovent Biotech Co., Ltd","has_results":false},{"nct_id":"NCT04682600","title":"The Sonic Incytes Liver Incytes System, Evaluation of Liver Fibrosis and Steatosis Versus MRE and MRI PDFF","phase":"NA","overall_status":"UNKNOWN","enrollment_count":164,"lead_sponsor_name":"Sonic Incytes","has_results":false},{"nct_id":"NCT04104321","title":"A Clinical Study to Evaluate the Efficacy and Safety of Aramchol in Subjects With NASH (ARMOR)","phase":"PHASE3","overall_status":"SUSPENDED","enrollment_count":157,"lead_sponsor_name":"Galmed Research and Development, Ltd.","has_results":true},{"nct_id":"NCT05384652","title":"Simultaneous Quantification of Liver Fat Content, Fatty Acid Composition, and Fibrosis Using Spin-lock MRI for Steatohepatitis Assessment","phase":"","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":140,"lead_sponsor_name":"Chinese University of Hong Kong","has_results":false},{"nct_id":"NCT02854605","title":"Evaluating the Safety, Tolerability, and Efficacy of GS-9674 in Participants With Nonalcoholic Steatohepatitis (NASH)","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":140,"lead_sponsor_name":"Gilead Sciences","has_results":true},{"nct_id":"NCT06216041","title":"To Evaluate the Safety, Tolerability, Pharmacokinetics and Food Effects of IMM-H014 in Healthy Subjects","phase":"PHASE1","overall_status":"RECRUITING","enrollment_count":138,"lead_sponsor_name":"Changchun Intellicrown Pharmaceutical Co. LTD","has_results":false},{"nct_id":"NCT02856555","title":"Study to Evaluate Safety, Tolerability, and Efficacy of GS-0976 in Adults With Nonalcoholic Steatohepatitis","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":127,"lead_sponsor_name":"Gilead Sciences","has_results":true},{"nct_id":"NCT04267393","title":"Safety and Effectiveness of BMS-986263 in Adults With Compensated Cirrhosis (Liver Disease) From Nonalcoholic Steatohepatitis (NASH)","phase":"PHASE2","overall_status":"TERMINATED","enrollment_count":124,"lead_sponsor_name":"Bristol-Myers Squibb","has_results":true},{"nct_id":"NCT02913105","title":"Safety, Tolerability, Pharmacokinetics and Efficacy of LMB763 in Patients With NASH","phase":"PHASE2","overall_status":"TERMINATED","enrollment_count":122,"lead_sponsor_name":"Novartis Pharmaceuticals","has_results":true},{"nct_id":"NCT02654002","title":"Study in Healthy Volunteers to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of GS-9674 (Cilofexor), and the Effect of Food on GS-9674 Pharmacokinetics and Pharmacodynamics","phase":"PHASE1","overall_status":"COMPLETED","enrollment_count":120,"lead_sponsor_name":"Gilead Sciences","has_results":true},{"nct_id":"NCT02754037","title":"Non-alcoholic Fatty Liver Disease Parametric PET (FLiPP) Study","phase":"","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":120,"lead_sponsor_name":"University of California, Davis","has_results":false},{"nct_id":"NCT04913090","title":"A Phase I Clinical Trial of XZP-5610 Tablets in Healthy Subjects","phase":"PHASE1","overall_status":"UNKNOWN","enrollment_count":112,"lead_sponsor_name":"Xuanzhu Biopharmaceutical Co., Ltd.","has_results":false},{"nct_id":"NCT03205150","title":"Effect of LIK066 on Reduction of Fatty Content in Livers of Obese Patients","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":107,"lead_sponsor_name":"Novartis Pharmaceuticals","has_results":true},{"nct_id":"NCT04977661","title":"Comparing the Effects of Vitamin E, Ursodeoxycholic Acid and Pentoxyfylline on Egyptian Non-alcoholic Steatohepatitis (NASH) Patients","phase":"PHASE4","overall_status":"COMPLETED","enrollment_count":102,"lead_sponsor_name":"Kafrelsheikh University","has_results":false},{"nct_id":"NCT03572465","title":"Quantitative Ultrasound Techniques for Diagnosis of Nonalcoholic Steatohepatitis","phase":"","overall_status":"RECRUITING","enrollment_count":102,"lead_sponsor_name":"Centre hospitalier de l'Université de Montréal (CHUM)","has_results":false},{"nct_id":"NCT06724913","title":"Efficacy and Tolerability of a Specialized Food Products for Dietary Therapeutic and Preventive Nutrition Based on Ice Cream (Ice Cream With Brazzein, Maltitol and Oligofructose; Ice Cream With Brazzein, Erythritol, Maltitol and Inulin) Compared to Standard (Sundae) Ice Cream","phase":"NA","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":100,"lead_sponsor_name":"Federal State Budgetary Scientific Institution \"Federal Research Centre of Nutrition, Biotechnology","has_results":false},{"nct_id":"NCT05591079","title":"A Study to Assess the Safety, Tolerability, Pharmacokinetics and Efficacy of CS0159 in Subjects With NASH","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":99,"lead_sponsor_name":"Cascade Pharmaceuticals, Inc","has_results":false},{"nct_id":"NCT03392779","title":"Study in Chinese Healthy Adults to Evaluate the Safety, Tolerability and Pharmacokinetics on ZSP1601, and the Effect of Food on ZSP1601 Pharmacokinetics","phase":"PHASE1","overall_status":"COMPLETED","enrollment_count":94,"lead_sponsor_name":"Guangdong Zhongsheng Pharmaceutical Co., Ltd.","has_results":false},{"nct_id":"NCT04521114","title":"Leronlimab (PRO 140) in Patients With Nonalcoholic Steatohepatitis","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":87,"lead_sponsor_name":"CytoDyn, Inc.","has_results":true},{"nct_id":"NCT04165343","title":"Evaluation of Multi-Organ Metabolism and Perfusion in NAFLD by Total Body Dynamic PET Scan on EXPLORER","phase":"","overall_status":"COMPLETED","enrollment_count":81,"lead_sponsor_name":"University of California, Davis","has_results":false},{"nct_id":"NCT06176079","title":"Hyperpolarized Pyruvate (13C) Magnetic Resonance Imaging In Patients With Fatty Liver Disease","phase":"","overall_status":"UNKNOWN","enrollment_count":80,"lead_sponsor_name":"Michael Ohliger, MD PhD","has_results":false},{"nct_id":"NCT05552274","title":"FTIH of ECC4703 in Healthy Volunteers","phase":"EARLY_PHASE1","overall_status":"COMPLETED","enrollment_count":75,"lead_sponsor_name":"Eccogene","has_results":false},{"nct_id":"NCT04019561","title":"A Study to Evaluate Safety and Pharmacodynamic Efficacy of 0382 in Obese Subjects With NAFLD/NASH.","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":74,"lead_sponsor_name":"MedImmune LLC","has_results":true},{"nct_id":"NCT04483947","title":"A Study to Assess Safety, Tolerability, PK and PD of AZD2693 in Non-alcoholic Steatohepatitis Patients","phase":"PHASE1","overall_status":"COMPLETED","enrollment_count":74,"lead_sponsor_name":"AstraZeneca","has_results":false},{"nct_id":"NCT02891408","title":"Study to Evaluate the Pharmacokinetics of Firsocostat or Fenofibrate in Adults With Normal and Impaired Hepatic Function","phase":"PHASE1","overall_status":"COMPLETED","enrollment_count":74,"lead_sponsor_name":"Gilead Sciences","has_results":true},{"nct_id":"NCT02466516","title":"Safety, Tolerability, and Efficacy of GS-4997 Alone or in Combination With Simtuzumab (SIM) in Adults With Nonalcoholic Steatohepatitis (NASH) and Fibrosis Stages F2-F3","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":72,"lead_sponsor_name":"Gilead Sciences","has_results":true},{"nct_id":"NCT05117489","title":"A Study Evaluating the Safety, Efficacy, and Pharmacokinetics of Miricorilant in Patients With Presumed Nonalcoholic Steatohepatitis (NASH)","phase":"PHASE1","overall_status":"COMPLETED","enrollment_count":70,"lead_sponsor_name":"Corcept Therapeutics","has_results":false},{"nct_id":"NCT04546984","title":"Multiple Dose Safety, Tolerability, PK，PD and Food Effect Study of HEC96719 in Healthy Adult Subjects","phase":"PHASE1","overall_status":"COMPLETED","enrollment_count":66,"lead_sponsor_name":"Sunshine Lake Pharma Co., Ltd.","has_results":false},{"nct_id":"NCT04194242","title":"The Tolerability , Pharmacokinetics and Pharmacodynamics Study of HEC96719 Tablets in Healthy Adult Subjects","phase":"PHASE1","overall_status":"COMPLETED","enrollment_count":64,"lead_sponsor_name":"Sunshine Lake Pharma Co., Ltd.","has_results":false},{"nct_id":"NCT02196831","title":"Tesamorelin Effects on Liver Fat and Histology in HIV","phase":"NA","overall_status":"COMPLETED","enrollment_count":61,"lead_sponsor_name":"Massachusetts General Hospital","has_results":true},{"nct_id":"NCT05842512","title":"Study of ADI-PEG 20 Versus Placebo in Subjects With NASH","phase":"PHASE2","overall_status":"RECRUITING","enrollment_count":60,"lead_sponsor_name":"Polaris Group","has_results":false}],"total":50},"guidelines":[],"source":"Drug Landscape verified database"}